Status: Finalised
First registered on:
08/08/2018
Last updated on:
01/03/2019
1. Study identification
EU PAS Register NumberEUPAS25192
Official titleSevere hypersensitivity reactions associated with high dose iv iron containing medicinal products
Study title acronym
Study typeOther: Pharmacoepidemiologic study with case-population design
Brief description of the studyEvaluation of severe hypersensitivity reactions after administration of high dose iv irons with respect to overall exposure in European countries by using information from existing data sources
Was this study requested by a regulator?No
Is the study required by a Risk Management Plan (RMP)?
Not applicable
Regulatory procedure number (RMP Category 1 and 2 studies only)
Other study registration identification numbers and URLs as applicable
2. Research centres and Investigator details
Coordinating study entity
Centre to which the investigator belongsIMS Health
Department/Research groupReal World Evidence Solutions
Organisation/affiliationIMS Health
Details of (Primary) lead investigator
Title Dr
Last name Annegret
First name Gohlke
Is this study being carried out with the collaboration of a research network?
No
Other centres where this study is being conducted
Not applicable (single centre)
Countries in which this study is being conducted
International study
Austria
Belgium
Bulgaria
Croatia
Czech Republic
Denmark
Estonia
Finland
France
Germany
Greece
Hungary
Ireland
Italy
Latvia
Lithuania
Netherlands
Norway
Poland
Portugal
Romania
Slovakia
Slovenia
Spain
Sweden
Switzerland
United Kingdom
3. Study timelines: initial administrative steps, progress reports and final report
PlannedActual
Date when funding contract was signed08/03/2018
Start date of data collection15/06/201802/07/2018
Start date of data analysis02/07/201816/07/2018
Date of interim report, if expected
Date of final study report31/12/201812/02/2019
4. Sources of funding
Please provide estimates of the percentage of funding by source for this study
Names(s)Approximate % funding
Pharmaceutical companiesVifor International AG100
Charities
Government body
Research councils
EU funding scheme
5. Contact details for enquiries
Scientific Enquiries
Title Mrs
Last name Ehlken
First name Birgit
Address line 1Landshuter Allee 10
Address line 2
Address line 3
CityMunich
Postcode80637
CountryGermany
Phone number (incl. country code)49-894579126400
Alternative phone number
Fax number (incl. country code)
Public Enquiries
Title Mrs
Last name Birgit
First name Ehlken
Address line 1Landshuter Allee 10
Address line 2
Address line 3
CityMunich
Postcode80637
CountryGermany
Phone number (incl. country code)49-89-4579126400
Alternative phone number
Fax number (incl. country code)
6. Study drug(s) information
Single-Constituent (Substance INN)FERRIC CARBOXYMALTOSE
Single-Constituent (Substance INN)IRON(III) ISOMALTOSIDE 1000
7. Medical conditions to be studied
Medical condition(s)Yes
Anaphylactoid shock
Anaphylactic reaction
Anaphylactoid shock
Anaphylactoid reaction
8. Population under study
Age
Adolescents (12 - 17 years)
Adults (18 - 44 years)
Adults (45 - 64 years)
Adults (65 - 74 years)
Adults (75 years and over)
Sex
Male
Female
9. Number of subjects
Estimated total number of subjects99999999
Additional information
not applicable, because this is case-population study
10. Source of data
Is this study being carried out with an established data source?Yes
Data sources registered with ENCePP
Data sources not registered with ENCePP
Vigibase, Sweden
IQVIA (IMS) Sales data, United Kingdom
Sources of data
Administrative database, e.g. claims database
Vigibase: WHO Program for International Drug Monitoring database for AE reporting
IQVIA (IMS) sales data: volume of drugs in retail and hospital setting in European countries
11. Scope of the study
What is the scope of the study?
case-population study
Primary scope : case-population study
12. Main objective(s)
What is the main objective of the study?
To evaluate the reported rate of anaphylactic/anaphylactoid reactions associated with single high dose IV iron products with respect to overall exposure of single iron products in European countries, including:
ferric carboxymaltose and iron isomaltoside
Are there primary outcomes?No
Are there secondary outcomes?No
13. Study design
What is the design of the study?
Pharmacoepidemiologic study with case-population design using established data sources
14. Follow-up of patients
Will patients be followed up?Not applicable/no follow-up
15. Data analysis plan
Please provide a brief summary of the analysis method
In a descriptive analysis reported rates of severe hypersensitivity AEs including anaphylactic reaction, anaphylactic shock, anaphylactoid reaction and anaphylactoid shock for the period 1 Jan 2014 – 31 Dec 2017 will be determined by number of reports divided by the number of 100 mg DEq (=DDD) of iron sold.
Odds Ratios and corresponding 95 % CI will be calculated.
16. ENCePP seal
Are you requesting the ENCePP seal for this study?
No
17. Full protocol
Not submitted
18. Study Results
Please list the 5 most relevant publications using data from your study
ReferenceLink to web-publication
None
19. Other relevant documents
Conflict(s) of interest of
investigator(s)Not submitted
Composition of Steering Group and
ObserversNot submitted
Other documentsNot
submitted
Signed Code of
Conduct Checklist
Not submitted
Signed Code of Conduct Declaration
Not submitted
Signed Checklist for Study
Protocols
Not submitted
